ALUMINIUM SULFATE - rezultati iskanja

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

vitrakvi larotrectinib (as sulfate) 25 mg hard capsule bottle

bayer australia ltd - larotrectinib sulfate, quantity: 30.7 mg - capsule, hard - excipient ingredients: gelatin; propylene glycol; dimethicone 12500; brilliant blue fcf aluminium lake; titanium dioxide; shellac; strong ammonia solution - vitrakvi (larotrectinib) has provisional approval in australia for the treatment of adult and paediatric patients with locally advanced or metastatic solid tumours that:,? have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion without a known acquired resistance mutation, ? are metastatic or where surgical resection is likely to result in severe morbidity, and ? have either progressed following treatment or who have no satisfactory alternative therapy. the decision to approve this indication has been made on the basis of objective response rate (orr) and duration of response from single arm clinical studies. the sponsor is required to submit further clinical data to confirm the clinical benefit of the medicine.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

vitrakvi larotrectinib (as sulfate) 100 mg hard capsule bottle

bayer australia ltd - larotrectinib sulfate, quantity: 122.9 mg - capsule, hard - excipient ingredients: titanium dioxide; shellac; gelatin; dimethicone 12500; propylene glycol; brilliant blue fcf aluminium lake; strong ammonia solution - vitrakvi (larotrectinib) has provisional approval in australia for the treatment of adult and paediatric patients with locally advanced or metastatic solid tumours that:,? have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion without a known acquired resistance mutation, ? are metastatic or where surgical resection is likely to result in severe morbidity, and ? have either progressed following treatment or who have no satisfactory alternative therapy. the decision to approve this indication has been made on the basis of objective response rate (orr) and duration of response from single arm clinical studies. the sponsor is required to submit further clinical data to confirm the clinical benefit of the medicine.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

eikance 0.01% atropine sulfate monohydrate 100 microgram/1 ml eye drops solution packed in single-dose ampoules

aspen pharmacare australia pty ltd - atropine sulfate monohydrate, quantity: 0.1027 mg/ml (equivalent: atropine sulfate, qty 0.1 mg/ml) - eye drops, solution - excipient ingredients: citric acid monohydrate; sodium chloride; hydrochloric acid; water for injections; sodium hydroxide - eikance 0.01% is indicated as a treatment to slow the progression of myopia in children aged from 4 to 14 years. atropine treatment may be initiated in children when myopia progresses greater than or equal to -1.0 d per year.

Kenija - angleščina - Pharmacy and Poisons Board

aluminium hydroxide tablets bp chewable tablet

cosmos limited rangwe road, off lunga lunga road, industrial - dried aluminium hydroxide bp - chewable tablet - 500mg - aluminium antacids compounds

Kenija - angleščina - Pharmacy and Poisons Board

centacid suspension oral suspension

centaur pharmaceuticals pvt. ltd. centaur house near grand hyatt vakola santacruz - aluminium hydroxide magnesium hydroxide… - oral suspension - aluminium hydroxide paste equivalent to dried… - aluminium antacids compounds